A brief energizer to kick off the morning before we dive in.

Employers are under pressure to make short-term decisions about obesity treatment, but the bigger challenge is managing long-term cardiometabolic risk. This opening keynote reframes obesity within a broader cardiometabolic context—connecting diabetes, cardiovascular disease, and downstream workforce impact—and sets the lens for the strategic decisions employers will face in 2026 and beyond.

This discussion explores what’s next in cardiometabolic care—from emerging therapies and devices to evolving care models—and how employers can balance access, sustainability, and outcomes.

As cardiometabolic care becomes more complex, employers are looking to technology to improve coordination, visibility, and oversight. This panel takes a practical look at how data, AI, and clinical integration can reduce fragmentation—where these tools add value and what employers should be considering as they evaluate new solutions.

GLP-1s have become the most immediate cardiometabolic intervention many employers face. This panel examines how employers are navigating access, cost, oversight, and employee demand today—highlighting tradeoffs, uncertainty, and the questions employers should be asking as they balance near-term pressure with longer-term sustainability. 

As employers respond to rising GLP-1 utilization and cardiometabolic costs, foundational drivers—nutrition, sleep, physical capacity, and recovery—often remain disconnected from core strategy.

This session explores how these upstream factors shape medication effectiveness, engagement, and long-term sustainability—and what it takes to treat them as infrastructure, not just wellness.

A brief, facilitated movement activity to re-energize before our afternoon sessions.

Cardiometabolic conditions are clinically interconnected but often managed through separate benefits, vendors, and care pathways. This panel examines why silos persist, how fragmentation undermines outcomes and cost control, and what employers need to know as they work to manage cardiometabolic risk more holistically.

Most employers do not yet have a fully formed cardiometabolic strategy. Instead, they are beginning to assemble a playbook—often in response to GLP-1 pressure, rising costs, and growing employee demand. This session takes an honest look at what employers are starting to put in place, where fragmentation persists, which tools belong in their long-term architecture, and which early decisions matter most as organizations move from reactive programs toward a more coherent approach to cardiometabolic risk.